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Abstract
The HIV-1 envelope gp120/gp41 glycoprotein complex plays a critical role in virus-host cell
membrane fusion and has been a focus for the development of HIV fusion inhibitors. In this paper,
we present the synthesis of dimers of HIV fusion inhibitor peptides C37H6 and CP32M, which
target the trimeric gp41 in the pre-hairpin intermediate state to inhibit membrane fusion. Reactive
peptide modules were synthesized using native chemical ligation and then assembled into dimers
with varying linker lengths using Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC) “click”
chemistry. Cell-cell fusion inhibition assays demonstrated that dimers with a (PEG)7 linker
showed enhanced antiviral potency over the corresponding monomers. Moreover, the bio-
orthogonal nature of the CuAAC “click” reaction provides a practical way to assemble
heterodimers of HIV fusion inhibitors. Heterodimers consisting of the T20-sensitive strain
inhibitor C37H6 and the T20-resistant strain inhibitor CP32M were produced that may have
broader spectrum activities against both T20-sensitive and T20-resistant strains.
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The human immunodeficiency virus type 1 (HIV-1) is an enveloped virus, and its envelope
glycoprotein complex gp120/gp41 plays a critical role in HIV entry into host cells. The
current model of virus entry (Figure 1A) involves binding of the trimeric gp120 to the host
cell CD4 receptor and chemokine co-receptors CCR5 or CXCR4. Upon binding, gp120
undergoes conformational changes and dissociates from gp41, which results in insertion of
the N-terminal fusion peptide of gp41 into the host cell membrane and formation of a pre-
hairpin intermediate. Later, the N-terminal heptad repeat 1 region (HR1) and the C-terminal
heptad repeat 2 region (HR2) of gp41 fold back to form a six-helix bundle. In this fusion
active hairpin structure, the virus membrane and the host membrane are brought close
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enough for fusion.1,2 HIV fusion inhibitor peptides derived from the HR2 region of gp41
(referred to as C-peptides) were discovered to prevent hairpin structure formation by binding
to the HR1 region of gp41 in the pre-hairpin intermediate. This stabilizes the pre-hairpin
structure and consequently inhibits membrane fusion and viral entry.3,4 Among these
peptides, T20 (also known as DP-178, Enfuvirtide, and Fuzeon)5,6 and C347 are well-
studied inhibitors with IC50 values in the nM range (Figure 1B). T20 is also the only
member of this class of peptide fusion inhibitors approved by FDA as an antiretroviral drug.
Although T20 has been successfully used in the treatment of HIV infection, a variety of
T20-resistant HIV mutation strains have been isolated from patients.8 Therefore, new potent
HIV fusion inhibitor peptides against T20-resistant HIV strains have been developed.9–15
Both structural and biochemical studies have demonstrated that gp120 and gp41 are active
as trimers.16,17 Because of this, both gp120 and gp41 have three binding sites for their
targets and for potential inhibitors. The trimeric states of gp120 and gp41 have been the
focus for development of more potent inhibitors and vaccine candidates utilizing
simultaneous multivalent interactions. Wang and co-workers have synthesized dimeric and
trimeric CD4-mimetic miniproteins that target the CD4-binding sites of trimeric gp120 and
block gp120 binding to CD4. These multivalent miniproteins showed enhanced antiviral
activity over the monovalent miniprotein.18,19 Trimeric N- and C-peptides of gp41, designed
by Tam and co-workers for mimicking the pre-hairpin intermediate of gp41, were more
potent than the corresponding monomers and may be useful as vaccine candidates for
blocking HIV infection.20,21 Recently, We and other groups also developed dimeric and
trimeric C-peptide HIV fusion inhibitors with improved potency.22–26 These studies
demonstrate that multivalent approaches to targeting gp120 and gp41 can be utilized to
increase inhibitor potency.
The Cu(I)-catalyzed azide-alkyne cycloaddition, termed CuAAC “click” chemistry, is a
highly chemoselective reaction that has been widely used to form selective conjugates of
small molecules, peptides, and proteins for drug discovery and investigations of biological
function.27–33 Recently, we have developed a novel strategy to synthesize homodimers and
heterodimers of expressed proteins and peptides via a combination of native chemical
ligation (NCL)34 and CuAAC.35 In this strategy, the N-terminus of proteins and peptides are
first functionalized with azide and alkyne groups by NCL. The azide and alkyne groups are
then coupled together to form protein homodimers or heterodimers through CuAAC. To
develop more potent fusion inhibitor peptides, we present the application of this strategy to
assemble homodimers of HIV fusion inhibitor peptides C37H6,36,37 an analog of the HIV
fusion inhibitor C34, and CP32M,9 a newly developed HIV fusion inhibitor against both
T20-sensitive and T20-resistant strains targeting the trimeric gp41 in the pre-hairpin
intermediate (peptide inhibitor sequences shown in Figure 1C). Moreover, the bio-
orthogonal nature of the CuAAC reaction also provides us a practical way to assemble
heterodimers of C37H6 and CP32M that are functionalized with alkyne and azide moieties
respectively. The heterodimers assembled in this way could have broader spectrum activities
against both T20-sensitive and T20-resistant strains due to the presence of both the T20-
sensitive strain inhibitor C37H6 and the T20-resistant strain inhibitor CP32M. Treatment of
HIV infection with heterodimers made up of monomeric HIV fusion inhibitors active
against different drug resistant strains could also potentially slow or prevent the
development of drug-resistance. Functionalization of peptides with alkyne and azide groups
by NCL requires alkyne and azide thioesters and N-terminal cysteine containing peptides
(Scheme 1), which were generated by tobacco etch virus NIa (TEV) protease cleavage.38 A
fusion protein, GPRT-C37H6, that contains a TEV protease cleavage sequence between the
carrier protein GPRT and C37H6 was expressed and purified from E. coli as described
previously.37 Treatment of this fusion protein with TEV protease released the C37H6
peptide with an N-terminal cysteine (Figure S1A). Due to the hydrophobic nature of the
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CP32M peptide, the carrier protein SUMO was used as the fusion partner because of its
ability to enhance protein expression and solubility.39,40 Similarly, the fusion protein
SUMO-CP32M that contains the TEV protease cleavage sequence was expressed, purified
and treated with TEV protease to produce N-terminal cysteine containing CP32M (Figure
S2A). The cleaved C37H6 and CP32M peptides were separated from their fusion partners
by Ni2+-NTA affinity chromatography, and then further purified by reverse phase HPLC
and lyophilized. The alkyne thioester 1 and the azide thioester 2 were synthesized as
described previously.35 An azide thioester 3 with a polyethylene glycol (PEG)7 linker was
also synthesized to allow the production of dimers with an extended linker between peptide
monomers (Scheme S1).
The alkyne functionalized C37H6 (alkyne-C37H6 4) and azide functionalized C37H6
(azide-C37H6 5 and azide-PEG-C37H6 6) were obtained by incubating 2 mg/mL of C37H6
with 4 mM alkyne thioester 1, and azide thioesters 2 and 3 respectively, in the presence of
30 mM sodium 2-mercaptoethanesulfonate in denaturing buffer (7 M guanidine
hydrochloride, 100 mM sodium phosphate pH 7.5) (Scheme 1B). After 24 h the reaction
mixtures were purified by reverse phase HPLC and lyophilized to give 4, 5 and 6 (Figure
S1B, C and D). The same reaction conditions were also used to produce alkyne-CP32M 7,
azide-CP32M 8 and azide-PEG-CP32M 9 (Scheme 1C, Figure S2B, C and D).
To assemble homodimers of HIV fusion inhibitors, alkyne functionalized peptide monomers
and azide functionalized peptide monomers were coupled together through CuAAC.
Incubation of alkyne-C37H6 4 with azide-C37H6 5 or azide-PEG-C37H6 6 in the presence
of 1 mM CuSO4 and 2 mM L-ascorbic acid in denaturing buffer gave the C37H6-C37H6
homodimer 10 or C37H6-PEG-C37H6 homodimer 11 with a short and long linker between
two monomers, respectively (Figure 2A and B). The dimer products were separated from the
unreacted monomers by size-exclusion chromatography and further purified by reverse
phase HPLC and lyophilized (74% yield for 10 and 63% yield for 11). The analytical HPLC
and ESI-MS profiles of purified homodimers 10 and 11 are shown in Figure 2C and D,
which indicates the desired products were obtained with high purity. CP32M-CP32M
homodimer 12 with a short linker and CP32M-PEG-CP32M homodimer 13 with a long
(PEG)7 linker were also produced, purified and characterized using the same procedures
(57% yield for 12 and 55% yield for 13) (Figure 3).
To examine whether the divalent HIV fusion inhibitors have increased antiviral activities
compared to monovalent inhibitors, the antiviral activities were examined using a luciferase-
based cell-cell fusion inhibition assay.41 Briefly, two cell lines, HL2/342 and TZM-bl43,
were used in this assay. The HL2/3 cell line stably expresses HIV Gag, Env, Tat, Rev and
Nef proteins. The TZM-bl indicator cell line stably expresses large amounts of CD4 and
CCR5 and contains integrated copies of the luciferase gene under control of the HIV-1
promoter. Fusion between HL2/3 cells and TZM-bl cells can be monitored by luciferase
activity induced by cell fusion, and can also be inhibited by the addition of HIV fusion
inhibitor peptides into the cell culture media. Results from three independent assays are
summarized in Table 1 (also see Figure S3).
As we expected, the bacterial expressed fusion inhibitors C37H6 and CP32M are active to
block cell-cell fusion with an IC50 of 4.4 nM and 3.3 nM, respectively. Although the
homodimers with a short linker, C37H6-C37H6 10 and CP32M-CP32M 12, showed very
little or even no improvement of potency over the corresponding monomers (1.6-fold and
0.8-fold, respectively), the homodimers with a long (PEG)7 linker, C37H6-PEG-C37H6 11
and CP32M-PEG-CP32M 13, showed approximately 4-fold enhanced antiviral potency over
the corresponding monomers. The difference in activities among the dimers with different
linker length indicates that the space between the two monomer units may have some
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influence on the activities of the dimers. The spacing in 10 and 12 might be too short to
allow the second peptide monomer of the dimer to reach the second binding site of trimeric
gp41 in the pre-hairpin state while the first monomer is simultaneously binding to the first
binding site of gp41. Therefore, these two dimers may only act as monomeric inhibitors. In
contrast, 11 and 13 have a longer (PEG)7 linker, which apparently gives the two monomer
units enough space to bind two different binding sites on trimeric gp41 simultaneously to
achieve higher affinity binding and consequently obtain enhanced antiviral potency.
In addition to homodimers, the bio-orthogonal nature of the CuAAC reaction also provides
us a more practical way to assemble heterodimers of HIV fusion inhibitors with broader
spectrum activities by joining a T20-sensitive strain inhibitor with a T20-resistant strain
inhibitor that are functionalized with alkyne and azide moieties respectively. As an example,
two heterodimers C37H6-CP32M 14 and C37H6-PEG-CP32M 15 were synthesized by
coupling azide-C37H6 5 and azide-PEG-C37H6 6 with alkyne-CP32M 7, respectively
(Figure 4A and B). After purification and lyophilization (68% yield for 14 and 56% yield for
15), the products were characterized by analytical HPLC and ESI-MS (Figure 4C and D),
which indicated the desired heterodimers were produced. The antiviral activities of 14 and
15 were determined by cell-cell fusion inhibition assays as shown in Table 1. Similar to the
homodimers 10 and 12, the heterodimer C37H6-CP32M 14 showed no improvement of
antiviral activity, presumably due to the short linker between the monomers. However, the
heterodimer C37H6-PEG-CP32M 15 inhibited the cell-cell fusion with an IC50 of 1.2 nM,
which was 3.7-fold more potent than the C37H6 monomer and 2.8-fold more potent than the
CP32M monomer. In addition to improved potency, the heterodimers of C37H6 and CP32M
should have broader activity against both T20-sensitive and T20-resistant virus strains.
Moreover, treatment of HIV infection with heterodimers of HIV fusion inhibitors could
potentially slow or prevent the development of drug-resistance. This is because the two
peptides in the heterodimer have different sequences and different binding sites on gp41,
and it will likely require more mutations to create resistance to the heterodimer than to either
monomeric inhibitor alone.
In conclusion, a series of homodimers and heterodimers of HIV fusion inhibitor peptides
C37H6 and CP32M have been assembled using a combination of NCL with CuAAC.
Peptide inhibitors were produced by recombinant protein expression and then ligated to
alkyne and azide linkers using NCL. Alkyne and azide adapted HIV fusion inhibitor
modules could then be assembled to produce homodimeric and heterodimeric inhibitors with
varied linker lengths by utilizing CuAAC. Cell-cell fusion inhibition assays demonstrated
that although the dimers with a short linker did not improve antiviral activities compared to
monomers, the dimers with a longer (PEG)7 linker did show about 4-fold enhanced antiviral
potency over the corresponding monomers. Furthermore, by synthesizing a heterodimer
consisting of T20-sensitive strain inhibitor C37H6 and T20-resistant strain inhibitor CP32M,
it is likely that the resulting heterodimeric inhibitor will have a broader spectrum activity
against both T20-sensitive and T20-resistant virus strains. Treatment of HIV infection with
heterodimers of HIV fusion inhibitors could also potentially slow or prevent the
development of drug-resistance. This strategy could be applied to assemble homodimers and
heterodimers, or even higher order multimers of different types of HIV inhibitors to create a
library of HIV inhibitors with potentially greater potency, broader specificity and less
chance for the development of drug-resistance.
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HIV fusion and HIV fusion inhibitors. (A) Schematic representation of the mechanism for
HIV membrane fusion and fusion inhibition by C-peptides.1,2 (B) Schematic representation
of structure of gp41, and the locations and sequences of HIV fusion inhibitor C34 and T20.
FP, fusion peptide; TR, tryptophan-rich domain; TM, transmembrane domain; CP,
cytoplasmic domain. (C) The sequences of C37H6 and CP32M.
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Synthesis of C37H6 homodimers. (A) Synthesis of C37H6-C37H6 homodimer 10. (B)
Synthesis of C37H6-PEG-C37H6 homodimer 11. (C) Analytical HPLC profile and ESI-MS
of 10, calcd 11419, found 11418. (D) Analytical HPLC profile and ESI-MS of 11, calcd
11873, found 11872.
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Synthesis of CP32M homodimers. (A) Synthesis of CP32M-CP32M homodimer 12. (B)
Synthesis of CP32M-PEG-CP32M homodimer 13. (C) Analytical HPLC profile and ESI-
MS of 12, calcd 8839, found 8838. (D) Analytical HPLC profile and ESI-MS of 13, calcd
9294, found 9294.
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Synthesis of C37H6-CP32M heterodimers. (A) Synthesis of C37H6-CP32M heterodimer 14.
(B) Synthesis of C37H6-PEG-CP32M heterodimer 15. (C) Analytical HPLC profile and
ESI-MS of 14, calcd 10130, found 10131. (D) Analytical HPLC profile and ESI-MS of 15,
calcd 10584, found 10584.
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Functionalization of C37H6 and CP32M with Alkyne and Azide Groups by NCL. (A)
Chemical Structure of alkyne and azide thioesters 1–3. (B) Synthesis of alkyne and azide
functionalized C37H6 4–6. (C) Synthesis of alkyne and azide functionalized CP32M 7–9.
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Table 1
Antiviral activities of the HIV fusion inhibitors






C37H6 4.4±0.1 1.0 -
CP32M 3.3±0.3 - 1.0
C37H6-C37H6 10 2.7±0.3 1.6 -
C37H6-PEG-C37H6 11 1.1±0.1 4.0 -
CP32M-CP32M 12 4.2±0.2 - 0.8
CP32M-PEG-CP32M 13 0.8±0.1 - 4.1
C37H6-CP32M 14 4.9±0.4 0.9 0.7
C37H6-PEG-CP32M 15 1.2±0.1 3.7 2.8
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